Rapport Therapeutics
RAPP
Insidertransaktionen und Aktienkurs 2024-2026
Alle Insidertrades bei Rapport Therapeutics
| Datum |
Typ |
Insider |
Position |
Ø-Preis |
Volumen |
|
27.7.2026
|
Verkauf |
Ceesay, Abraham |
Chief Executive Officer |
42,4 $ |
93.061 $ |
|
14.7.2026
|
Verkauf |
Ceesay, Abraham |
Chief Executive Officer |
40,2 $ |
328.437 $ |
|
30.6.2026
|
Verkauf |
Gault, Cheryl |
Chief Operating Officer |
41,7 $ |
415.799 $ |
|
29.6.2026
|
Verkauf |
Ceesay, Abraham |
Chief Executive Officer |
40,0 $ |
327.398 $ |
|
26.5.2026
|
Verkauf |
Third Rock Ventures V, L.p. |
Zehn-Prozent-Eigentümer |
40,0 $ |
743.753 $ |
|
11.5.2026
|
Verkauf |
Third Rock Ventures V, L.p. |
Zehn-Prozent-Eigentümer |
40,2 $ |
5.377.323 $ |
|
8.5.2026
|
Verkauf |
Third Rock Ventures V, L.p. |
Zehn-Prozent-Eigentümer |
40,3 $ |
202.256 $ |
|
7.5.2026
|
Verkauf |
Third Rock Ventures V, L.p. |
Zehn-Prozent-Eigentümer |
40,1 $ |
10.892.651 $ |
|
17.4.2026
|
Verkauf |
Yeleswaram, Krishnaswamy |
Chief Development Officer |
40,0 $ |
808.844 $ |
|
17.4.2026
|
Verkauf |
Third Rock Ventures V, L.p. |
Zehn-Prozent-Eigentümer |
40,3 $ |
17.175.244 $ |
|
14.4.2026
|
Verkauf |
Yeleswaram, Krishnaswamy |
Chief Development Officer |
35,1 $ |
357.797 $ |
|
13.4.2026
|
Verkauf |
Yeleswaram, Krishnaswamy |
Chief Development Officer |
35,0 $ |
320.537 $ |
|
10.4.2026
|
Verkauf |
Yeleswaram, Krishnaswamy |
Chief Development Officer |
35,0 $ |
17.490 $ |
|
8.4.2026
|
Verkauf |
Yeleswaram, Krishnaswamy |
Chief Development Officer |
34,9 $ |
12.564 $ |
|
30.3.2026
|
Verkauf |
Gault, Cheryl |
Chief Operating Officer |
28,3 $ |
281.857 $ |
|
25.3.2026
|
Verkauf |
Yeleswaram, Krishnaswamy |
Chief Development Officer |
30,0 $ |
303.355 $ |
|
5.3.2026
|
Verkauf |
Gault, Cheryl |
Chief Operating Officer |
28,9 $ |
58.265 $ |
|
18.2.2026
|
Verkauf |
Ceesay, Abraham |
Chief Executive Officer |
29,4 $ |
320.373 $ |
|
17.2.2026
|
Verkauf |
Bredt, David |
Chief Scientific Officer |
28,9 $ |
246.655 $ |
|
20.1.2026
|
Verkauf |
Ceesay, Abraham |
Chief Executive Officer |
26,1 $ |
285.070 $ |
|
15.1.2026
|
Verkauf |
Bredt, David |
Chief Scientific Officer |
27,1 $ |
228.132 $ |
|
31.12.2025
|
Verkauf |
Yeleswaram, Krishnaswamy |
Chief Development Officer |
30,0 $ |
85.342 $ |
|
31.12.2025
|
Verkauf |
Bredt, David |
Chief Scientific Officer |
30,0 $ |
197.338 $ |
|
17.12.2025
|
Verkauf |
Ceesay, Abraham |
Chief Executive Officer |
30,0 $ |
323.509 $ |
|
15.12.2025
|
Verkauf |
Bredt, David |
Chief Scientific Officer |
30,3 $ |
255.130 $ |
|
26.11.2025
|
Verkauf |
Gault, Cheryl |
Chief Operating Officer |
30,1 $ |
150.487 $ |
|
17.11.2025
|
Verkauf |
Bredt, David |
Chief Scientific Officer |
25,1 $ |
214.091 $ |
|
17.11.2025
|
Verkauf |
Ceesay, Abraham |
Chief Executive Officer |
25,2 $ |
275.048 $ |
|
15.10.2025
|
Verkauf |
Ceesay, Abraham |
Chief Executive Officer |
26,0 $ |
281.729 $ |
|
15.10.2025
|
Verkauf |
Bredt, David |
Chief Scientific Officer |
26,0 $ |
219.197 $ |
|
17.9.2025
|
Verkauf |
Ceesay, Abraham |
Chief Executive Officer |
26,6 $ |
2.011.197 $ |
|
15.9.2025
|
Verkauf |
Bredt, David |
Chief Scientific Officer |
24,3 $ |
205.649 $ |
|
12.9.2025
|
Kauf |
Paul, Steven M. |
Aufsichtsrat |
24,7 $ |
1.027.112 $ |
|
12.9.2025
|
Kauf |
Huber, Reid M. |
Aufsichtsrat |
24,5 $ |
499.374 $ |
|
11.9.2025
|
Kauf |
Young, Wendy B. |
Aufsichtsrat |
22,6 $ |
79.100 $ |
|
8.9.2025
|
Verkauf |
Gault, Cheryl |
Chief Operating Officer |
38,3 $ |
191.650 $ |
|
15.8.2025
|
Verkauf |
Bredt, David |
Chief Scientific Officer |
15,4 $ |
127.466 $ |
|
15.7.2025
|
Verkauf |
Bredt, David |
Chief Scientific Officer |
14,0 $ |
118.962 $ |
|
16.6.2025
|
Verkauf |
Bredt, David |
Chief Scientific Officer |
11,0 $ |
93.522 $ |
|
15.5.2025
|
Verkauf |
Bredt, David |
Chief Scientific Officer |
9,6 $ |
81.262 $ |
|
15.4.2025
|
Verkauf |
Bredt, David |
Chief Scientific Officer |
9,6 $ |
81.310 $ |
|
14.3.2025
|
Verkauf |
Bredt, David |
Chief Scientific Officer |
10,8 $ |
92.205 $ |
|
13.3.2025
|
Kauf |
Ignelzi, Troy A. |
Chief Financial Officer |
10,0 $ |
998 $ |
|
12.3.2025
|
Kauf |
Young, Wendy B. |
Aufsichtsrat |
10,2 $ |
61.250 $ |
|
12.3.2025
|
Kauf |
Ignelzi, Troy A. |
Chief Financial Officer |
10,1 $ |
99.990 $ |
Alle Angaben ohne Gewähr! Keine Empfehlung/Beratung! © U.S. Securities and Exchange Commission (SEC)
Insidertrades in Telegram
Verfolge die Insiderkäufe in Echtzeit per Push in unserem Telegram-Channel.
Jetzt beitreten